Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Chinese Patients With Focal-Onset Seizures: An Observational, Prospective Study

被引:17
|
作者
Zhang, Ranran [1 ]
Qiao, Shan [2 ]
Fang, Xiqin [1 ]
Wang, Kemo [1 ]
Shi, Yanting [1 ]
Du, Qianwen [1 ]
Yang, Tingting [1 ]
Liu, Xuewu [1 ,3 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Neurol, Jinan, Peoples R China
[2] Shandong First Med Univ, Affiliated Hosp 1, Dept Neurol, Jinan, Peoples R China
[3] Shandong Univ, Inst Epilepsy, Jinan, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2021年 / 12卷
基金
中国国家自然科学基金;
关键词
epilepsy; anti-seizure medication; focal seizures; perampanel; seizure freedom; ILAE COMMISSION; POSITION PAPER; REAL-LIFE; EPILEPSY; CLASSIFICATION; SAFETY;
D O I
10.3389/fneur.2021.731566
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To evaluate the efficacy and tolerability of adjunctive perampanel (PER) in Chinese patients with focal-onset seizures, with or without secondarily generalized tonic-clonic seizures.</p> Methods: Fifty-six patients aged 14-72 years were recruited consecutively in this single-center prospective observational study. All patients received PER as add-on treatment on the basis of clinical judgment. Seizure frequency, adverse events (AEs), and retention rates were obtained at 3 and 6 months after PER introduction.</p> Results: The overall response rates were 60 and 71.1% after 3 and 6 months, respectively, and the freedom of seizures at the same points were reached in 8 and 15.8%. The retention rates were 89.3% at the 3-month follow-up and 67.9% at the 6-month follow-up. The overall incidence of adverse events was 55.4%. The leading reported AEs were dizziness (39.3%) and somnolence (25%).</p> Conclusions: Our study confirmed the efficacy and tolerability of adjunctive PER in Chinese patients in real-life conditions. Based on our treatment experience, a lower maintenance dose of PER would be needed in Chinese patients.</p>
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures
    Tyrlikova, Ivana
    Brazdil, Milan
    Rektor, Ivan
    Tyrlik, Michal
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (01) : 5 - 16
  • [22] Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study
    Winter, Yaroslav
    Dargham, Raya Abou
    Tobon, Susana Patino
    Groppa, Sergiu
    Fuest, Sven
    CNS DRUGS, 2024, 38 (09) : 733 - 742
  • [23] Perampanel As Adjunctive Therapy in Patients with Partial-Onset Seizures
    Plosker, Greg L.
    CNS DRUGS, 2012, 26 (12) : 1085 - 1096
  • [24] Effectiveness, Safety and Tolerability of Perampanel in Pediatric and Adolescent Patients with Focal-Onset and Generalized-Onset Seizures: Evidence from Clinical Practice
    Auvin, S.
    Garcia-Ron, A.
    Gil-Lopez, F.
    Shankar, R.
    Yamamoto, T.
    Ngo, L.
    Villanueva, V.
    ANNALS OF NEUROLOGY, 2022, 92 : S97 - S97
  • [25] Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures:A real-world experience in eastern China
    Xu, Sha
    Xu, Zheng-yan-ran
    Zheng, Yuanyuan
    Miao, Pu
    Feng, Jianhua
    Guo, Yi
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2023, 110 : 231 - 237
  • [26] Effect of low dose (4 mg/day) perampanel on efficacy and safety outcomes from a mirroring clinical practice study of adjunctive perampanel in adults and adolescents with focal-onset seizures
    Giallonardo, A. T.
    Aguglia, U.
    Goldman, S.
    Chiacchiaretta, M.
    Gentile, A.
    Patten, A.
    EPILEPSIA, 2022, 63 : 128 - 129
  • [27] Long-Term Efficacy and Safety of Adjunctive Perampanel in Elderly Patients with Focal-Onset Seizures by Concomitant Anti-Seizure Medication (ASM) Use
    Marawar, Rohit
    Leppik, Ilo E.
    Wechsler, Robert T.
    Patten, Anna
    Ngo, Leock Y.
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 53 - 54
  • [28] Study 512 Design: Perampanel as first adjunctive therapy in patients aged ≥12 years with focal-onset seizures or generalised tonic-clonic seizures associated with genetic generalised epilepsy
    Burd, S.
    Assenza, G.
    Quintas, S.
    Gil Lopez, F. J.
    Wagner, J.
    Patten, A.
    Sainz-Fuertes, R.
    Lagarde, S.
    Sejbaek, T.
    Vlasov, P.
    Kharkovskiy, V.
    Lebedeva, A.
    EPILEPSIA, 2023, 64 : 293 - 293
  • [29] Efficacy and Safety of Perampanel in Children with Drug-Resistant Focal-Onset Seizures: A Retrospective Review
    Elmardenly, Ahmed
    Aljehani, Zekra
    Tamim, Abdullah
    Alyazidi, Anas
    Muthaffar, Osama
    CHILDREN-BASEL, 2023, 10 (06):
  • [30] Ampa study (a mirroring clinical practice study of perampanel in adults and adolescents) design: Real-world prospective study of perampanel as add-on therapy for focal-onset seizures
    D'Aniello, Alfredo
    Giallonardo, Anna Teresa
    Mecarelli, Oriano
    Aguglia, Umberto
    Assenza, Giovanni
    Meletti, Stefano
    De Giorgis, Valentina
    Bonanni, Enrica
    Michelucci, Roberto
    Cerminara, Caterina
    Romeo, Antonino
    De Liso, Paola
    Copetti, Massimiliano
    Gentile, Anna
    Chiacchiaretta, Martina
    Di Gennaro, Giancarlo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 177 - 177